Effectiveness of reboxetine in treatment of outpatient children and adolescents with attention deficit-hyperactivity disorder with comorbid anxiety disorders.

• Main Authors: Forough Riahi, Ashraf Tashakori, Sakineh Izadi-Mazidi, Mohammad Salehi-Veysi
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2013-12-01
• Series: Iranian Journal of Psychiatry
• Subjects: Attention deficit-hyperactivity disorder (ADHD); Conners’ Parent questionnaire; Hamilton’s Anxiety Rating Scale; Reboxetine
• Online Access: https://ijps.tums.ac.ir/index.php/ijps/article/view/144
• ISSN: 1735-4587; 2008-2215

Some previous studies have reported that ADHD is often comorbid with anxiety disorders. The aim of the present study was to evaluate the effectiveness of reboxetine in treating outpatient children and adolescents with ADHD and comorbid anxiety disorders.In this open-label study, 25 outpatient children and adolescents, aged 6-16 years were selected by convenient sampling and underwent treatment with 4mg reboxetine for four weeks. Data were collected at baseline, two weeks and four weeks after the start of the medication using Conners' Parent Questionnaire, Hamilton's Rating Scale for Anxiety, Clinical Global Assessment Scale, Clinical Global Impression-Severity Scale and Side Effects Form. Data were analyzed using repeated measure, analyses of variance (ANOVA), Tukey post hoc test and paired t-test.There were significant reduction in the total score of ADHD (F = 31.441; P